found that glioblastoma cells treated with EGFR and MET inhibitors can develop resistance via FGFR signaling and that simultaneously inhibiting EGFR, FGFR, and MET overcomes the resistance by knocking out more downstream pathways (124). This evidence concerns the gene EGFR and glioblastoma.